Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connolly, D. C.
Right arrow Articles by Hamilton, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connolly, D. C.
Right arrow Articles by Hamilton, T. C.
[Cancer Research 63, 1389-1397, March 15, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer1

Denise C. Connolly2, Rudi Bao3, Alexander Yu Nikitin, Kasie C. Stephens, Timothy W. Poole4, Xiang Hua, Skye S. Harris, Barbara C. Vanderhyden and Thomas C. Hamilton

Ovarian Cancer Program [D. C. C., R. B., K. C. S., T. W. P., S. S. H., T. C. H.] and Transgenic Mouse Facility [X. H.], Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111; Department of Biomedical Sciences, Cornell University, Ithaca, New York, 14853 [A. Y. N.]; and Departments of Cellular and Molecular Medicine, and Obstetrics and Gynecology, University of Ottawa, and Ottawa Regional Cancer Centre, Ottawa, Ontario K1H 1C4, Canada [B. C. V.]

In women, >80% of malignant ovarian tumors are of epithelial origin. Early detection of these tumors is very challenging,and extensive i.p. dissemination is common by the time of diagnosis.The lack of adequate geneticmouse models of ovarian carcinomas significantly delays advances in early detection and treatment. We report that female transgenic mice expressing the transforming region of SV40 under control of the Mullerian inhibitory substance type II receptor gene promoter develop bilateral ovarian tumors in ~50% of cases. Histologically, these tumors are poorly differentiated carcinomas with occasional cysts and papillary structures present at the surface of the ovary. These tumors disseminate i.p., invade omentum, and form ascites as do human ovarian carcinomas. The epithelial origin of these tumors is supported by detection of cytokeratins 8 and 19, and the absence of {alpha}-inhibin, a protein characteristically expressed in normal granulosa cells and most granulosa cell tumors. Cell lines derived from the ascites exhibit the properties of epithelial ovarian cancer, such as anchorage-independent growth, tumorigenicity in immunocompromised mice, expression of epithelial cell markers, and organotropic implantation. The availability of a transgenic mouse model of disseminated ovarian carcinoma and respective cell lines should advance our understanding of this neoplasm, and serve as a useful tool for the evaluation of emerging detection and treatment strategies.




This article has been cited by other articles:


Home page
 JCOHome page
C. N. Landen Jr, M. J. Birrer, and A. K. Sood
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Wang, Z. Zhang, Y. Lu, R. Yao, D. Jia, W. Wen, M. LaRegina, K. Crist, R. Lubet, and M. You
Enhanced Susceptibility to Chemical Induction of Ovarian Tumors in Mice with a Germ Line p53 Mutation
Mol. Cancer Res., January 1, 2008; 6(1): 99 - 109.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Renlund, R. Pieretti-Vanmarcke, F. H. O'Neill, L. Zhang, P. K. Donahoe, and J. Teixeira
c-Jun N-terminal Kinase Inhibitor II (SP600125) Activates Mullerian Inhibiting Substance Type II Receptor-Mediated Signal Transduction
Endocrinology, January 1, 2008; 149(1): 108 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. K. Deeb, A. M. Michalowska, C.-y. Yoon, S. M. Krummey, M. J. Hoenerhoff, C. Kavanaugh, M.-c. Li, F. J. Demayo, I. Linnoila, C.-x. Deng, et al.
Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis
Cancer Res., September 1, 2007; 67(17): 8065 - 8080.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. E. Burdette, R. M. Oliver, V. Ulyanov, S. M. Kilen, K. E. Mayo, and T. K. Woodruff
Ovarian Epithelial Inclusion Cysts in Chronically Superovulated CD1 and Smad2 Dominant-Negative Mice
Endocrinology, August 1, 2007; 148(8): 3595 - 3604.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
S. M El-Naggar, M. T Malik, A. Martin, J. P Moore, M. Proctor, T. Hamid, and S. S Kakar
Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice
J. Endocrinol., July 1, 2007; 194(1): 179 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan
Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells
Cancer Res., April 15, 2007; 67(8): 3683 - 3690.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W.-L. Yang, K. Q. Cai, J. L. Smedberg, E. R. Smith, A. Klein-Szanto, T. C. Hamilton, and X.-X. Xu
A Reduction of Cyclooxygenase 2 Gene Dosage Counters the Ovarian Morphological Aging and Tumor Phenotype in Wv Mice
Am. J. Pathol., April 1, 2007; 170(4): 1325 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mabuchi, D. A. Altomare, D. C. Connolly, A. Klein-Szanto, S. Litwin, M. K. Hoelzle, H. H. Hensley, T. C. Hamilton, and J. R. Testa
RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer
Cancer Res., March 15, 2007; 67(6): 2408 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. DelloRusso, P. L. Welcsh, W. Wang, R. L. Garcia, M.-C. King, and E. M. Swisher
Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation
Mol. Cancer Res., January 1, 2007; 5(1): 35 - 45.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Yang, D. G. Rosen, I. Mercado-Uribe, J. A. Colacino, G. B. Mills, R. C. Bast Jr, C. Zhou, and J. Liu
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells
Carcinogenesis, January 1, 2007; 28(1): 174 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Robinson, I. van Bruggen, A. Segal, M. Dunham, A. Sherwood, F. Koentgen, B. W.S. Robinson, and R. A. Lake
A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent.
Cancer Res., November 15, 2006; 66(22): 10786 - 10794.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer
PNAS, November 14, 2006; 103(46): 17426 - 17431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Singh and L. Johnson
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
Clin. Cancer Res., September 15, 2006; 12(18): 5312 - 5328.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q.-a. Yuan, H. H. Simmons, M. K. Robinson, M. Russeva, W. A. Marasco, and G. P. Adams
Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer.
Mol. Cancer Ther., August 1, 2006; 5(8): 2096 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, D. M. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. T. MacLaughlin, and P. K. Donahoe
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
PNAS, July 25, 2006; 103(30): 11154 - 11159.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
Y. Zhan, A. Fujino, D. T. MacLaughlin, T. F. Manganaro, P. P. Szotek, N. A. Arango, J. Teixeira, and P. K. Donahoe
Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression
Development, June 15, 2006; 133(12): 2359 - 2369.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. V. Subramanian, T. M. Bui Nguyen, A. M. Truskinovsky, J. Tolar, B. R. Blazar, and S. Ramakrishnan
Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival.
Cancer Res., April 15, 2006; 66(8): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Daikoku, S. Tranguch, I. N. Trofimova, D. M. Dinulescu, T. Jacks, A. Yu. Nikitin, D. C. Connolly, and S. K. Dey
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.
Cancer Res., March 1, 2006; 66(5): 2527 - 2531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo
Clin. Cancer Res., March 1, 2006; 12(5): 1593 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Boerboom, M. Paquet, M. Hsieh, J. Liu, S. P. Jamin, R. R. Behringer, J. Sirois, M. M. Taketo, and J. S. Richards
Misregulated Wnt/{beta}-Catenin Signaling Leads to Ovarian Granulosa Cell Tumor Development
Cancer Res., October 15, 2005; 65(20): 9206 - 9215.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Boyd
Mouse Models of Gynecologic Pathology
N. Engl. J. Med., May 26, 2005; 352(21): 2240 - 2242.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey
Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer
Cancer Res., May 1, 2005; 65(9): 3735 - 3744.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. L. Stewart, T. D. Querec, A. R. Ochman, B. N. Gruver, R. Bao, J. S. Babb, T. S. Wong, T. Koutroukides, A. D. Pinnola, A. Klein-Szanto, et al.
Characterization of a Carcinogenesis Rat Model of Ovarian Preneoplasia and Neoplasia
Cancer Res., November 15, 2004; 64(22): 8177 - 8183.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al.
A Genetically Defined Model for Human Ovarian Cancer
Cancer Res., March 1, 2004; 64(5): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. A. Stronach, G. C. Sellar, C. Blenkiron, G. J. Rabiasz, K. J. Taylor, E. P. Miller, C. E. Massie, A. Al-Nafussi, J. F. Smyth, D. J. Porteous, et al.
Identification of Clinically Relevant Genes on Chromosome 11 in a Functional Model of Ovarian Cancer Tumor Suppression
Cancer Res., December 15, 2003; 63(24): 8648 - 8655.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Flesken-Nikitin, K.-C. Choi, J. P. Eng, E. N. Shmidt, and A. Yu. Nikitin
Induction of Carcinogenesis by Concurrent Inactivation of p53 and Rb1 in the Mouse Ovarian Surface Epithelium
Cancer Res., July 1, 2003; 63(13): 3459 - 3463.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.